ASCO is the largest clinical oncology meeting in the US, and it runs on public information long before the show floor opens: accepted abstracts and the exhibitor list both surface weeks ahead. For any account list with an active oncology program on it, that makes ASCO one of the highest-leverage pre-show windows on the entire conference calendar.
What ASCO is
The American Society of Clinical Oncology Annual Meeting draws oncologists, clinical trial sponsors, and essentially every company with an active oncology program, whether they are presenting trial results, exhibiting, or simply sending clinical and business-development staff to attend. Exhibitors range from the sponsor companies themselves to oncology-focused CROs, CDMOs with oncology manufacturing capability, and diagnostics and tools vendors that serve oncology labs and trial sites.
Because it is filtered tightly to oncology, ASCO is a sharper signal than a broad show like BIO International for any account with a cancer-focused program, and a weaker one for accounts working outside oncology entirely.
The GTM signal at ASCO
Exhibiting is the strongest company-level signal, real budget committed to visibility in front of an oncology-specific audience. A named presenter on an accepted abstract is the sharpest contact-level hook available anywhere on the calendar: a specific person, a specific trial or dataset, and a specific date, all public before the talk happens. Attending without exhibiting or presenting is the weakest of the three signals but still a legitimate, timely reason to reach out. See selling around life science conferences for how to weigh the three against each other.
The outreach window
Accepted abstracts and the exhibitor floor both become public well before the meeting opens, generally enough lead time to cross-reference against a fit-qualified account list, confirm which contacts are presenting, and reach out with a specific reason tied to their talk or booth before the show, when calendars are still open. During the show, outreach still works but competes with a packed clinical schedule. After ASCO closes, a reference to a specific session or conversation holds up for a few weeks; much beyond that it reads as a stale callback to an old event.
Who this matters most for
A CRO running or pursuing oncology trials gets the most direct value from ASCO of any show on the calendar, since presenting authors and exhibiting sponsors are both a near-perfect match for that buyer. A CDMO with oncology manufacturing capability should track which sponsors are exhibiting or presenting as a proxy for who is advancing an oncology asset toward the next stage. A tools or diagnostics vendor serving oncology labs or trial sites should treat ASCO as one of the tightest-fit shows available for that specific buyer.